Association of CYP2C19 genotype with type 2 diabetes

Carlos Hoyo-Vadillo, Jaime Garcia-Mena, Adán Valladares, Caterina R. Venturelli, Niels Wacher-Rodarte, Jesús Kumate, Miguel Cruz

.

DOI: 10.4236/health.2010.210174                

Abstract

Background: CYP2C19 is a major isoform of cytochrome P450 that metabolizes a number of commonly prescribed drugs such as omeprazole, diazepam, tolbutamide and propranolol. Its expression is regulated by the constitutive androstane receptor (CAR), involved in glucocorticoids synthesis. Since a number of crossliniks have been described for CYPs and some hormones, an association of CYP2C19 with type 2 diabetes is likely. Methods: Two groups were studied, 352 diagnosed with type 2 diabetes patients and 342 healthy volunteers form Mexico City. Both groups were tested for CYP2C19*2 and *3 alleles. We carried out an allelic discrimination using TaqMan assay for *2, and used FRET sensor and anchor probes for *3. Results: Ninety one percent of the subjects had the wild type allele, 9% have the *2 allele; no subject presented the *3 allele. The CYP2C19*2 allele is associated with type 2 diabetes (p = 0.012). Admixmap program was used to correct the admixture of this population and get the correlation. This was further confirmed in a linear model with a 67% power and by the method of Strom and Wienker for association on subjects within the mean range of Amerindian ancestry only (60%). Conclusion: Type 2 diabetes patients have significatly more *2 allele than healthy volunteers, more evident for the patients with the homocygous genotype.

Keywords

Pharmacogenomics; CYP2C19; Type 2 Diabetes; Mexicans; Allele Frequency

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Chan, J., Donalson, L.M., Kushwaha, R.S., Ferdinan- dusse, S., VandeBerg, J.F. and VandeBerg, J.L. (2008) Differential expression of hepatic genes involved in cholesterol homeostasis in high- and low-responding strains of laboratory opossums. Metabolism, 57(5), 718-724.
[2]	Bertilsson, L., Dahl, M.L., Dalen, P. and Al-Shurbaji, A. (2002) Molecular genetics of CYP2D6: Clinical rele- vance with focus on psychotropic drugs. British Journal of Clinical Pharmacology, 53(2), 111-122.
[3]	Wedlund, P.J. (2000) The CYP2C19 enzyme polymer- phism. Pharmacology, 61(3), 174-183.
[4]	Hamdy, S.I., Hiratsuka, M., Narahara, K., El-Enany, M., Moursi, N., Ahmed, M.S., et al. (2002) Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. British Journal of Clinical Pharmacology, 53(6), 596- 603.
[5]	Bravo-Villalta, H.V., Yamamoto, K., Nakamura, K., Baya, A., Okada, Y. and Horiuchi, R. (2005) Genetic poly- morphism of CYP2C9 and CYP2C19 in a Bolivian population: An investigative and comparative study. European Journal of Clinical Pharmacology, 61(3), 179- 184.
[6]	Isaza, C., Henao, J., Martinez, J.H., Arias, J.C. and Beltran, L. (2007) Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. BMC Cli- nical Pharmacology, 7(1), 6.
[7]	Jurima-Romet, M., Goldstein, J.A., LeBelle, M., Aubin, R.A., Foster, B.C., Walop, W., et al. (1996) CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharma- cogenetics, 6(4), 329-339.
[8]	Lewis, D.F. (2003) Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xeno- biotics: A compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Current Medicinal Chemistry, 10(19), 1955-1972.
[9]	Cavalli-Sforza, L.L., Menozzi, P. and Piazza, A. (1994) The history and geography of human genes. Princeton University Press, Princeton.
[10]	Handschin, C., Podvinec, M. and Meyer, U.A. (2000) CXR, a chicken xenobiotic-sensing orphan nuclear receptor, is related to both mammalian pregnane X receptor (PXR) and constitutive androstane receptor (CAR). Proceedings of National Academic Sciences of USA, 97(20), 10769-10774.
[11]	Martinez-Marignac, V.L., Valladares, A., Cameron, E., Chan, A., Perera, A., Globus-Goldberg, R., et al. (2007) Admixture in Mexico City: implications for admixture mapping of type 2 diabetes genetic risk factors. Hum Genet, 120(6), 807-819.
[12]	Borlak, J. and Thum, T. (2002) Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis. Clinical Chemistry, 48(9), 1592-1594.
[13]	Strom, T.M.W. (2009) Case-control studies. http://ihg2. helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl
[14]	Sasieni, P.D. (1997) From genotypes to genes: Doubling the sample size. Biometrics, 53(4), 1253-1261.
[15]	Ourlin, J.C., Handschin, C., Kaufmann, M. and Meyer, U.A. (2002) A link between cholesterol levels and phenobarbital induction of cytochromes P450. Biochemistry and Biophysics Research Communication, 291(2), 378- 384.
[16]	Handschin, C., Podvinec, M., Amherd, R., Looser, R., Ourlin, J.C. and Meyer, U.A. (2002) Cholesterol and bile acids regulate xenosensor signaling in drug-mediated induction of cytochromes P450. Journal of Biological Chemistry, 277(33), 29561-29567.
[17]	Kohalmy, K., Tamasi, V., Kobori, L., Sarvary, E., Pascussi, J.M., Porrogi, P., et al. (2007) Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor. Drug Metabolism and Disposition, 35(9), 1495-1501.
[18]	Z. Wang, S.D. Hall, J.F. Maya, L. Li, A. Asghar, J.C. Gorski, Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. British Journal of Clinical Pharmacology, 55(1), 77-85.
[19]	S. Elmi, N. A. Sallam, M. M. Rahman, X. Teng, A. L. Hunter, F. Moien-Afshari, et al. (2008) Sulfaphenazole treatment restores endothelium-dependent vasodilation in diabetic mice. Vascular Pharmacology, 48(1), 1-8.
[20]	Sim, S.C. (2008) Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http:// www.cypalleles.ki.se/
[21]	Chen, Y., Ferguson, S.S., Negishi, M. and Goldstein, J.A. (2003) Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2- C19 promoter. Molecular Pharmacology, 64(2), 316-324.
[22]	Gerbal-Chaloin, S., Pascussi, J.M., Pichard-Garcia, L., Daujat, M., Waechter, F., Fabre, J.M., et al. (2001) Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metabolism and Disposition, 29(3), 242-251.
[23]	Handschin, C. and Meyer, U.A. (2005) Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Archives of Biochemistry and Biophysics, 433(2), 387-396.
[24]	Handschin, C., Gnerre, C., Fraser, D.J., Martinez- Jimenez, C., Jover, R. and Meyer, U.A. (2005) Species- specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys, 434(1), 75-85.